REFERENCES
- Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 2001; 112: 1575–1585
- Kiernan MC, Hart IK, Bostock H. Excitability properties of motor axons in patients with spontaneous motor unit activity. J Neurol Neurosurg Psychiatry 2001; 70: 56–64
- Kiernan MC, Lin CS, Andersen KV, et al. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001; 24: 883–892
- Weiss G. Surla possibilite de rendle comparables entre eux les appareils servant a l'excitation electrique. Arch Ital Biol 1901; 35: 413–446
- Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998; 21: 137-158
- Priori A, Cinnante C, Pesenti A, et al. Distinctive abnormalities of motor axonal strength—duration properties in multifocal motor neuropathy and in motor neurone disease. Brain 2002; 125: 2481–2490
- Mogyoros I, Kiernan MC, Burke D, et al. Excitability changes in human sensory and motor axons during hyperventilation and ischaemia. Brain 1997; 120: 317–325
- Mogyoros I, Kiernan MC, Burke D, et al. Strength—duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 1998; 121: 851–859
- Choi SS, Chan KF, Ng HK, et al. Colchicine-induced myopathy and neuropathy. Hong Kong Med J 1999; 5: 204–207
- Kuncl RW, George EB. Toxic neuropathies and myopathies. Curr Opin Neurol 1993; 6: 695–704
- Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987; 18: 1562–1568
- Yerdelen D, Uysal H, Koc F, et al. Effects of sex and age on strength—duration properties. Clin Neurophysiol 2006; 117: 2069–2072
- Mogyoros I, Kiernan MC, Burke D. Strength—duration properties of human peripheral nerve. Brain 1996; 119: 439–447
- Chang E, Dellon AL, Dellon ES, et al. Developing a model of colchicine neuropathy. Microsurgery 2002; 22: 46–48
- Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: Guidelines for the prophylactic use of colchicine in gout. Rheumatol 1991; 18: 264–269
- Schiff D, Drislane FW. Rapid-onset colchicine myoneuropathy. Arthritis Rheum 1992; 35: 1535–1536
- Paulson JC, McClure WO. Inhibition of axoplasmic transport by colchicine, podophyllotoxin, and vinblastine: An effect on microtubu les. Ann NY Acad Sci 1975; 253: 517–527
- Pilar G, Landmesser L. Axotomy mimicked by localized colchicine application. Science 1972; 177: 1116–1118
- Jackson P, Diamond J. Colchicine block of cholinesterase transport in rabbit sensory nerves without interference with the long-term viability of the axons. Brain Res 1977; 130: 579–584
- Nodera H, Kaji R. Nerve excitability testing and its clinical application to neuromuscular diseases. Clin Neurophysiol 2006; 117: 1902–1916
- Birol A, Ulkatan S, Kocak M, et al. Peripheral neuropathy in Behcet's disease. Dermatol 2004; 31: 455–459
- Namer IJ, Karabudak R, Zileli T, et al. Peripheral nervous system involvement in Behcet's disease. Case report and review of the literature. Eur Neurol 1987; 26: 235–240
- Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behcet disease. A review. Neurologist 2005; 11: 80–89
- Altiparmak MR, Pamuk ON, Pamuk GE, et al. Colchicine neuromyopathy: A report of six cases. Clin Exp Rheumatol 2002; 20 (4 Suppl. 26): S13—S16